BetterLife and Collaborators to Submit Key Joint Research Publication Post published:September 7, 2022 Post category:Press Release
BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity with Possible Nootropic Effects Similar to That of LSD Without Hallucinogenic Side Effects Post published:August 25, 2022 Post category:Press Release
BetterLife Secures Additional Mitacs Funding in Collaboration with Carleton University Research Team for BETR-001 Preclinical Depression Studies Post published:July 7, 2022 Post category:Press Release
BetterLife To Participate at the H.C. Wainwright 1st Annual Mental Health Conference Post published:June 23, 2022 Post category:Press Release
BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity in Preclinical Model Post published:February 15, 2022 Post category:Press Release
BetterLife Receives FDA Response On Its Pre-IND Application For Major Depressive Disorder (MDD) Treatment With BETR-001 Post published:January 20, 2022 Post category:Press Release
BetterLife Obtains Positive In Vivo Oral Bioavailability, Food Effect and Pharmacokinetics Data for BETR-001 Post published:January 18, 2022 Post category:Press Release
BetterLife Files Patent for TD-0148A for Treatment of Cluster Headaches and Related Disorders Post published:September 27, 2021 Post category:Press Release
BetterLife Announces Closing of a Non-Brokered Private Placement Post published:May 14, 2021 Post category:Press Release
BetterLife Files Patent for Invention of Novel Subcutaneous Implant to Prevent Drug Diversion of LSD and Other Psychedelic Drugs Post published:April 29, 2021 Post category:Press Release